Heron Therapeutics (HRTX) Change in Acquisitions & Divestments (2016 - 2026)

Heron Therapeutics has reported Change in Acquisitions & Divestments for 11 years, with the latest figure at $12.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments fell 50.12% year-over-year to $12.6 million; the trailing twelve-month figure through Mar 2026 stood at $54.4 million (down 50.38% YoY), and the FY2025 full-year result was $67.0 million, down 45.73% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $12.6 million, up from $7.1 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $51.0 million in Q1 2023, with the low at $7.1 million in Q4 2025.
• Historically, Change in Acquisitions & Divestments has averaged $26.7 million across 5 years, with a median of $25.2 million in 2025.
• Annual changes were most pronounced in 2024 — Change in Acquisitions & Divestments jumped 122.56% — and 2025, when it sank 70.87%.
• Heron Therapeutics' Change in Acquisitions & Divestments stood at $21.0 million in 2022, then decreased by 29.76% to $14.8 million in 2023, then surged by 65.23% to $24.4 million in 2024, then slumped by 70.87% to $7.1 million in 2025, then jumped by 77.34% to $12.6 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $12.6 million (Q1 2026), $7.1 million (Q4 2025), and $18.0 million (Q3 2025), per Business Quant data.